How is oral semaglutide described in the supplied record?

The record describes an oral tablet form of semaglutide, a GLP-1 peptide also associated there with Ozempic and Wegovy. It names Rybelsus for type 2 diabetes, attributes oral uptake to SNAC, and reports lower diabetes doses alongside a 25 mg oral weight-management product described as the first oral obesity GLP-1.

Why does the record associate SNAC with this tablet?

The supplied mechanism text characterizes semaglutide as a GLP-1 receptor agonist and SNAC as sodium N-(8-[2-hydroxybenzoyl]amino) caprylate. It says SNAC changes local pH, reduces peptide breakdown, and supports movement across the gastric lining into circulation. The text associates these conditions with an empty stomach, <4oz water, and a 30 minute interval before food or extra fluid.

What regulatory status does the supplied record report?

The record reports FDA approval for Rybelsus in type 2 diabetes, cardiovascular-risk reduction dated Oct 2025, and oral Wegovy 25 mg for weight management dated Dec 2025.

What adverse effects are listed?

The listed adverse effects are nausea, vomiting, diarrhea, constipation, pancreatitis, gallbladder problems, and thyroid C-cell tumors under a boxed warning. Nausea is reported at up to 50 %; the source says experiences may differ with dose, duration, and individual health factors.

What dose data does the supplied record contain?

The community row reports limited dose data, directs readers to research protocols, and gives the range as See research dosing. A separate research row lists 3mg daily (starting), long-term / chronic use, and the supplied administration text. These are source-recorded entries rather than personalized dosing advice.

Weight Loss FDA Approved - approved for specific uses

Semaglutide Oral

Q: What regulatory status does the supplied record report?

The record reports FDA approval for Rybelsus in type 2 diabetes, cardiovascular-risk reduction dated Oct 2025, and oral Wegovy 25 mg for weight management dated Dec 2025.

Q: What adverse effects are listed?

The listed adverse effects are nausea, vomiting, diarrhea, constipation, pancreatitis, gallbladder problems, and thyroid C-cell tumors under a boxed warning. Nausea is reported at up to 50 %; the source says experiences may differ with dose, duration, and individual health factors.

Q: What dose data does the supplied record contain?

The community row reports limited dose data, directs readers to research protocols, and gives the range as See research dosing. A separate research row lists 3mg daily (starting), long-term / chronic use, and the supplied administration text. These are source-recorded entries rather than personalized dosing advice.

Also known as: Semaglutide Oral, Rybelsus, Semaglutide

At a glance

PeptiGuide dataset · reviewed Aug 2026

What it is

Oral semaglutide formulation described with SNAC-assisted absorption.

Status

FDA Approved

Evidence level: human clinical evidence

Typical dose

Limited community data available

Oral tablet on empty stomach with <4oz water

Researched for

Oral use in type 2 diabetes and weight management.

Trial progress

PrePreclinical
IPhase I
IIPhase II
IIIPhase III
IVPhase IV
FDAFDA approved

FDA approved - FDA-approved for specific uses with established human evidence

Use the tools

In plain language

The supplied record identifies an oral semaglutide tablet and names SNAC as its absorption enhancer.
It lists Rybelsus and reports FDA-approved status, including a 25 mg oral weight-management product.
The source describes human-trial programs and cautions that oral absorption is sensitive to administration conditions.

How it's thought to work

The supplied record identifies semaglutide as a receptor and attributes appetite reduction, slower gastric emptying, and glucose-dependent insulin release to it. It describes co-formulation with SNAC (sodium N-(8-[2-hydroxybenzoyl]amino) caprylate), which is said to alter local gastric pH, limit digestive breakdown, and facilitate passage through the gastric lining into blood. These mechanistic statements were not independently corroborated in the input.

What the research shows

Where the research stands

The supplied record characterizes the evidence as published human-trial research. It reports that PIONEER included more than 9,500 people with type 2 diabetes, with A1C changes of roughly 0.6 to 1.4 percentage points and modest weight loss; sitagliptin and empagliflozin are named as comparators. For PIONEER PLUS, cited as published in The Lancet, the record compares 25 mg and 50 mg with 14 mg and reports greater A1C and weight reductions at the higher amounts. It reports an OASIS 1 comparison of 15.1 % weight loss at 50 mg versus 2.4 % with placebo. For OASIS 4 (NEJM, 2025), it states 13.6 % loss at a 64 week endpoint on 25 mg, described as comparable with injectable Wegovy. These reported results require review against the cited publications.

What it shows

✓ Human clinical evidence

FDA-approved for specific uses with established human evidence

△ Limitations

Use only according to approved labeling and qualified medical guidance.

Bottom line: FDA approved for Rybelsus in type 2 diabetes; cardiovascular-risk reduction (Oct 2025); and weight management with oral Wegovy 25 mg (Dec 2025), which the source calls the first oral GLP-1 for obesity. FDA Approved

Typical dosing

CommunityCommunity dataset

Limited community data available

See research protocols

Range: See research dosing

This is a community-reported entry, not an individualized dosing recommendation.

Research dosing

Indication-specificApproved for specific uses - study doses are indication-specific

Doses observed in studies

3mg daily (starting)

FDA Approved Labeling - Prescribed dose

Use only according to approved labeling and qualified medical guidance.

Duration: Long-term / chronic use
Administration: Oral tablet on empty stomach with <4oz water

Timing & administration

Best time to take

Morning, immediately after waking, on an empty stomach

Once daily

Food recommendation

The source associates empty-stomach administration with a 30 minute separation from food and additional fluid.

Why this timing?

The FDA label requires fasted morning administration with no more than 4 ounces of water and at least a 30-minute wait before food, beverages, or other oral medicines.

Possible side effects

Not everyone experiences these. Individual responses vary with dose, duration, and personal factors.

Nausea
Vomiting
Diarrhea
Constipation
Pancreatitis
Gallbladder problems
Thyroid C-cell tumors

Not everyone experiences side effects, and severity can vary by context, purity, route, and individual health factors.

Sources

PubMed ClinicalTrials.gov FDA.gov

Frequently asked questions

Sequence

H-Aib-EGTFTSDVSSYLEGQAAK(1)EFIAWLVRGRG; C18-diacid-gamma-Glu-2xOEG linked at Lys20

One open dataset

Every fact on this page - doses, side effects, references - comes from the same PeptiGuide dataset that powers the Tracker, Compare, and the Lab.

Browse the dataset

Save to my research list Get updates on Semaglutide Oral

Educational resource, not medical advice. Talk to your clinician before acting on anything here.

Community discussion

Comments are moderated before they appear. Keep it evidence-focused.

Semaglutide Oral

In plain languageIn plain language

How it's thought to workHow it's thought to work

What the research showsWhat the research shows

Typical dosing

Research dosing

Timing & administrationTiming & administration

Possible side effectsPossible side effects

SourcesSources

Frequently asked questionsFrequently asked questions